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Abstract
Background: The implementation of an innovative and sustainable professional pharmacy service in routine
care requires substantial resources borne by the pharmacy owner. Although a community pharmacy is a
business setting, few studies have examined cost as a potential barrier to widespread implementation.
Implementation costs, as the cost impact of an implementation effort, can be significant and hamper the
decision to invest from the provider perspective. Traditional financial planning tools can be used to analyse
and support business decision to implement a service by assessing the net impact of a new service on the
provider’s budget. This study aimed to estimate the implementation costs and the break-even point of an
interprofessional medication adherence program for chronic patients in Switzerland. The program combines
motivational interviews, medication adherence electronic monitoring and feedback reports to patient and
physicians.
Methods: We used a 3-step approach: (i) micro-costing analysis: identification of implementation activities,
quantification and valuation of required resources. Implementation costs, including service support costs and
direct delivery costs, were analysed according to the implementation phase (installation, initial implementation, and full
operation); (ii) break-even analysis: estimation of the required number of patients to follow up with to ensure that the
generated revenue exceeded the total cost; and (iii) univariate sensitivity analyses.
Results: The estimated total cost of the installation phase was 8481 CHF, more than half of which represented the cost
of the equipment. Direct delivery costs were 666 CHF per patient per year, with 68% of this value associated with the
cost of workforce time. According to the Swiss national reimbursement system, a minimal of 16 [10–27] patients was
required to cover the implementation costs of the installation phase. This break-even point decreased to 13 patients in
the initial and full operation phases.
Conclusions: These estimates lead to a better understanding of the real cost of implementing a professional
pharmacy service in routine care. In a Swiss context, the current medication adherence support fee-for-service
system allows pharmacists to reach the break-even point. Such information is important for community
pharmacists to guide their implementation strategies. The replication of similar analyses in other settings and countries is
paramount.
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Background
In 2011, the World Health Organization (WHO) and the
International Pharmaceutical Federation (FIP) officially
adopted changes in the practices of community pharma-
cists from the delivery of medicines to a collaborative,
person-centred care process [1, 2]. In practice, a variety of
professional pharmacy services are now available in phar-
macies, ranging from screening services to prescription re-
newals, medication reviews, and adherence-enhancing
services. From a healthcare system perspective, some of
these services are effective [3–7] and cost-effective in ex-
perimental contexts [8] and can increasingly be charged
as fees-for-services [9, 10].
Medication nonadherence is endemic and decreases the
cost-effectiveness of chronic treatments [11–13]. In 2004,
the Community Pharmacy Center of the Department of
Ambulatory Care and Community Medicine (Policlinique
Médicale Universitaire, PMU), University of Lausanne
(Switzerland) developed and implemented an interprofes-
sional medication adherence program (IMAP) for chronic
patients. It consists of a multifactorial, semi-structured
intervention combining individualised, short but repeated
motivational interviews, medication adherence electronic
monitors (EMs) (MEMS, Aardex MWV, Switzerland) and
feedback to the patient. A secure web platform allows the
pharmacist to record the patients’ data, provide adherence
feedback to the patient during the interview, report to the
physician and other professionals, and use the electronic
records to guide the intervention from one interview to
the next one. The program has been described in detail
elsewhere [14, 15]. For example, in 2014, 268 patients
were followed up by the Community Pharmacy Center:
187 HIV patients, 28 multiple sclerosis patients, 9 oncol-
ogy patients and 44 patients with various chronic diseases
(e.g., hypertension, type 2 diabetes and chronic dialysis)
[15]. Currently, the program is being implemented in
some voluntary community pharmacies in the
French-speaking part of Switzerland for HIV patients [16],
multiple sclerosis patients [17] and patients with type 2
diabetes [18]. Published literature on the program in HIV
patients showed an increased medication adherence and
persistence among participants compared to a control
group at 6 months (quasi-experimental study, n = 32) [19].
Moreover, the number of undetectable HIV patients in-
creased during the 11-month program (retrospective ana-
lysis, n = 104) [14]. Finally, the program significantly
improved retention in care at 6 and 12months (retro-
spective analysis, n = 762) [20]. Other findings in the lit-
erature assessing the effectiveness and cost-effectiveness
of interventions to improve adherence in HIV and chronic
patients corroborate these positive results [21–23].
Despite these encouraging developments, the imple-
mentation of professional pharmacy services in routine
care faces certain challenges [24–26]. Among other
factors investigated in the literature, cost is a potential
barrier to widespread implementation [27–29]. Imple-
mentation costs is defined as the cost impact of an im-
plementation effort [28]. They can be significant and
may hamper the provider’s decision to invest [30, 31].
They occur during three different phases of the imple-
mentation process [32–34]: installation phase (i.e., the
preparation of the pharmacy and service provider to de-
liver the service), initial implementation phase (aimed to
experiment the service provision to a small number of
patients) and full operation phase (i.e., the full imple-
mentation and the provision of the service in routine
care) [32]. Within these phases, two components of im-
plementation costs can be distinguished [31]: direct
service delivery costs and service support costs. First,
direct service delivery costs vary with each additional pa-
tient (i.e., variable costs) and include all costs associated
with the delivery of the service, primarily labour costs.
Second, service support costs occur both in the installa-
tion phase, as start-up costs (e.g., initial staff training,
equipment), and in the implementation and full oper-
ation phases (e.g., continuous training, supervision meet-
ings). These costs are independent of the number of
patients (i.e., fixed costs). Finally, the true implementa-
tion cost of a professional pharmacy service notably de-
pends upon the complexity of the service, the
complexity of the used implementation strategies, and
the setting of service delivery (complexity and over-
heads) [28].
The literature often focuses on the direct service deliv-
ery costs, and rarely includes service support costs, or it
values at best the initial staff training. However, the im-
plementation of a sustainable, innovative service requires
substantial resources to organise, engage and integrate
the pharmacy in a novel philosophy of practices and
business strategy. To be financially feasible and viable,
the total revenue generated by the implementation of
the service must at least cover the total cost of its imple-
mentation. Hence, traditional financial planning tools
can help to analyse and support the business decision to
implement a service by assessing the net impact of a
new service on the provider’s budget [35]. The
break-even analysis (BEA) can identify the price of a ser-
vice and/or determine the volume of service needed to
break even financially [36]. In a context of a
fee-for-services fixed price, BEA is interesting to identify
the required number of patients to follow up with (“the
break-even point”) to ensure that the generated revenue
will exceed the total cost.
This pragmatic study aimed to estimate implementa-
tion costs and the break-even point (in terms of the
number of patients to follow up with) based on a
real-world activity of the interprofessional medication
adherence program for chronic patients.
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Methods
Cost analysis
This analysis assessed the costs of a community phar-
macy to implement the program. Because it focused on
the implementation costs from the provider’s perspec-
tive, patient and societal costs were not considered. We
performed a micro-costing analysis that included three
steps [37, 38]: (i) identifying the relevant activities neces-
sary to implement, maintain and deliver the program,
(ii) quantifying the required resources for each activity
(e.g., labour, space, material), and (iii) valuing a unit cost
for each resource. The analysis is presented in accord-
ance with the project management tool: PERT chart
(Program Evaluation and Review Technique) used to
schedule, organize, and coordinate tasks within the pro-
ject. The cost estimates were expressed in Swiss Francs
(1 CHF = 0.88€ = $0.99, http://www.xe.com, 11/13/2018).
The initial staff training and investment, as well as the
equipment, were amortisable over a 5-year amortisation
period.
Identification of activities & quantification of required
resources
The identification of the relevant activities and the quan-
tification of required resources were based on the ex-
perience of the Community Pharmacy of the PMU,
University of Lausanne (Switzerland) [15]. The cost esti-
mates were validated by consensus with two external
community pharmacy owners established in the same
Swiss canton (canton de Vaud) (JFL, CRO). Implementa-
tion costs occurring in the different phases of the imple-
mentation process (installation, initial and full operation
phases) were differentiated by service support costs and
direct service delivery costs according to the classifica-
tion of Garcia-Cardenas et al. (2016) (see Fig. 1). Service
support costs in the installation phase corresponded to
start-up costs, required before the inclusion of the first
patient.
Service support costs
Professional training: Pharmacist’s education
During the installation phase, the initial pharmacist
training focused on (1) knowledge of medication adher-
ence and (2) motivational interviewing skills. First, the
pharmacist attended a 10-h adherence course organised
into 5 modules: (i) introduction to medication adher-
ence, (ii) theoretical frameworks of medication adher-
ence, (iii) medication adherence interventions, (iv)
structure of medication adherence interviews, and (v)
case studies. Second, the pharmacist was trained in mo-
tivational interviewing during four 4-h sessions [15].
Then, during the initial and full operation phases, the
Fig. 1 Activities and associated cost items to implement and deliver the program (PERT graph). Activities performed by the community
pharmacist. Activities performed by the pharmacy technician. Activities performed by both of them. CHF: Swiss Francs; CP: community
pharmacist; EMs: electronic monitors; FU: follow-up: hr.: hour; min: minutes; n/a: not applicable; pt.: patient. * Including: writing the organizational
procedures, preparing the support material, participating to coaching meetings, lauching the local networks and training in the web platform. **
Including patient leaflets, information and education material
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pharmacist attended one day of continuous education
per year, consisting of an update on medication adher-
ence or motivational interviewing. For instance, at the
Community Pharmacy Center of the PMU, a 1-h adher-
ence internal meeting is organised every 6 to 8 weeks for
educational purposes and for discussing complex case
studies [15]. In the analysis, we considered the labour
cost (i.e., time spent on training) and the course registra-
tion fee.
Professional training: Pharmacy technician’s training
In the analysis, we considered a day of internal training
per each new pharmacy technician during the installa-
tion phase. The objectives were to train technicians on
the handling of EMs, the secure uploading of EMs data
and counting tablets. Moreover, during the initial and
full operation phases, the technicians participated in the
same education internal meetings along with the phar-
macists. Initial training costs were amortised over 5
years.
Implementation strategies
In the installation phase, the pharmacist-technician duo
needed two days to prepare and organise the delivery of
the service. This time included the development of the
planning process, the writing of procedures and the
preparation of support material. To ensure the quality of
the service and the fidelity in its delivery, the service is
ISO certified at the Community Pharmacy Center of the
PMU and all procedures are written and made available
to the team at any time. The cost of support material
was estimated by expert opinion, including patient leaf-
lets and information and education material. In the ini-
tial and full operation phases, these efforts decreased but
were still considered.
Equipment
According to Swiss law, a community pharmacy who of-
fers a professional pharmacy service must have a privacy
room or area that allows confidentiality for a
face-to-face interview with the patient. Based on this
fact, we assumed that pharmacists already had this space
(including a computer) available for the medication ad-
herence program, hence their acquisition costs were not
considered in the analysis. As part of the equipment, we
included the cost of the licence for a secure web plat-
form to collect electronic patient data (i.e., SISPha®).
This licence also comprises the implementation and
technical support, including coaching meetings to guide
the pharmacist during the interview and to edit the re-
port for the physician and the nursing team (http://
www.sispha.com). The cost of this annual licence was
considered during all three phases of the implementa-
tion process.
Direct service delivery costs
The average duration of the follow-up per patient was
estimated at one year in accordance with PMU data
(median: 333 days; IQR25: 138; IQR75: 799) [15]. The fre-
quency of interviews with the pharmacist depends on
the patient’s needs, with a more intensive support activ-
ity at the beginning of follow-up. Hence, this analysis
considered the theoretical frequency of interviews start-
ing at once a month for the first three months and then
once a trimester thereafter (associated with prescription
refill). Accordingly, we estimated one inclusion and six
follow-up visits per patient for the first year.
Workforce time
The variable costs associated with the delivery of the ser-
vice included the pharmacist time (patient interviews,
adherence report editing, collaboration with the phys-
ician) and the technician time (EMs handling). Since
2011, the Community Pharmacy Center of the PMU
routinely collects all time, except for coordination. Thus,
we used these established median durations [15]. How-
ever, because these data are self-reported and from a
program in operation since 2004, they are affected by
the professional’s experience and may also be underesti-
mated. Therefore, in accordance with experts, we added
20% to the original PMU time data to more precisely es-
timate the real time needed for implementing the service
in inexperienced community pharmacies. Additionally,
we evaluated the time required for the coordination, in-
cluding time spent on launching local networks between
the pharmacist and the physicians and all interprofes-
sional contacts during a patient follow-up (estimated by
expert opinion).
Electronic monitoring
Health insurance in Switzerland effectively reimburses
the medication adherence program for all polypharmacy
patients, defined as people who are simultaneously pre-
scribed at least three chronic treatments and who are re-
ferred by their physician to their pharmacist because of
a history or a risk of poor adherence. Therefore, in this
analysis, we decided to include the costs of three EMs
per patient. The EM unit cost was annualised to con-
sider a battery life of two years, including the cost of the
hardware required to read EMs data.
Valuation of unit cost for each resource
Labour cost
The hourly labour costs for health professionals were es-
timated by expert opinion based on the Swiss salary
scale in the canton of Vaud (http://www.vd.ch). This
scale defines a salary level per profession (classes ranging
from 1 to 18) according to professional experience
(grades ranging from 0 to 26). The annual gross salary
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for a mid-career professional corresponded to class
11/grade 13 for a community pharmacist and class 4/
grade 13 for a pharmacy technician. According to the
finance department at the PMU, a multiplier coeffi-
cient (22%) was applied to consider social security
contributions and reflect the full cost to the em-
ployer. Finally, the number of annual working hours
used corresponded to the usual number of effective
working hours in Switzerland (42 h30 per week ex-
cluding holidays, absenteeism and downtime).
Space cost
We considered the opportunity cost (i.e., the value of
the resource in an alternative use) of the interview pri-
vate room/confidentiality area used for the delivery of
the service. To estimate the hourly cost of this space,
the size of the room was fixed by expert opinion to ten
square metres. The cost per square metre included the
annual rent, maintenance and utility fees, derived from
the annual cost survey on Swiss pharmacies in 2014
(“RoKA” report, http://www.pharmasuisse.org/de/). The
total annual cost was divided by the mean opening hours
in the canton (57 h per week in the “RoKA” report).
Break-even analysis (BEA)
The BEA formula can determine the volume of services
(i.e., quantity, expressed in terms of the number of
followed-up patients) needed to ensure that the generated
revenues exceed the costs [36] (see Fig. 2). The “price”
corresponded to the fixed total revenue per patient (i.e.,
the total fees charged by the pharmacist to the Swiss
health insurances, depending on the number of chronic
medications taken by the patient). In our case, it included
a medication adherence support fee-for-service (21.60
CHF per week) and the sale of a pill organiser (18 CHF
per quarter) per patient (http://www.pharmasuisse.org/de/
). We estimated the break-even point using Microsoft Of-
fice Excel 2007 software.
Sensitivity analyses
Univariate sensitivity analyses were performed to assess
the impact of the uncertainty generated by estimated pa-
rameters (other things being equal). This uncertainty
takes into account the risk management of the activity
(e.g. longer interview time with complex patients). Only
the parameters estimated to have the greatest impact on
the model output were assessed:
(i) the professional delivery time using interquartile
ranges (IQR25, IQR75) [15];
(ii) the pharmacist and technician labour costs using
+/− 20% of the base case values to account for the im-
pact of professional experience level;
(iii) the number of EMs per patient using one and four
EMs for the minimum and the maximum scenarios; and
(iv) the doubling of trained professionals to ensure a
full-time capacity to deliver the program.
Results
In the installation phase of the implementation process,
the total cost was estimated at 8481 CHF, more than half
of which represented the cost of the equipment (see
Table 1). Service support costs were lower in the initial
and full operation phases. The variable costs (i.e., direct
service delivery costs) were 666 CHF per patient per
year, with 68% representing the cost of workforce time.
According to the national reimbursement system and
the cost estimation, a minimal of 16 patients was
required to cover the implementation costs of the instal-
lation phase (see Fig. 3). In this case, service support
costs represented 39% of total costs. The break-even
point decreased to 13 patients in the initial and full
Fig. 2 Break-even analysis (BEA) formula
Table 1 Estimation of implementation costs
Cost
(CHF)
Contribution
(%)
Installation phase
(1) Service support costs 8481 100%
Initial training* 741 9%
Implementation strategies 3240 38%
Organisation 2240 26%
Support material ** 1000 12%
Equipment 4500 53%
Initial and full operation phases
(1) Service support costs (per year) 6680 100%
Continuous training 1120 17%
Implementation strategies 1060 16%
Organisation 560 8%
Support material ** 500 7%
Equipment 4500 67%
(2) Direct service delivery costs (per patient
per year)
666 100%
Workforce time 455 68%
Pharmacist 353 53%
Technician 102 15%
Electronic monitoring (EMs) 201 30%
Space 10 2%
*Amortised over 5 years
**Including patient leaflets, information and education material
CHF = Swiss Francs
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operation phases. The sensitivity analyses estimated the
break-even points to be between 10 and 27 patients, ac-
cording to the implementation phase and the scenario
(see Table 2).
Discussion
These estimates provide a better understanding of the
real cost of implementing an interprofessional medica-
tion adherence program for chronic patients in Swiss
community pharmacies. Due to the heterogeneity in in-
terventions, data collections, item costs, or national pro-
fessional costs, it is difficult to directly compare with
other similar studies [32, 39]. However, all these studies
consistently indicated that service support costs in the
installation phase are substantial and that professional
costs are the primary drivers of direct service delivery
costs.
Our study is the one of the first to estimate the service
support costs, distinguished during the implementation
phases. Their significance supports the development of
their valuation in cost analysis and economic evaluation.
Service support costs, as described in this analysis, are re-
quired to guarantee the delivery of a high and standardised
quality level service, but could also hamper the decision to
invest from the provider perspective. In Switzerland, phar-
macists’ training in advanced patient-oriented services is
part of their postgraduate or continuous education. Today,
the costs of such trainings are therefore borne by the phar-
macy owners. However, this could change over time in ac-
cordance with the current curricula reform in Switzerland.
Fig. 3 Break-even analysis
Table 2 Sensitivity Analyses
Base case Professional cost Professional delivery time Number of EMs Doubling of trained professionals
– Min Max Min Max Min Max
Installation phase
(1) Service support costs 8481 7971 9106 8481 8481 8481 8481 9222
Initial and full operation phases
(1) Service support costs 6680 6344 7016 6680 6680 6680 6680 7800
(2) Direct service delivery costs 666 575 757 508 881 532 733 666
Revenue 1195.2 1195.2 1195.2 1195.2 1195.2 1195.2 1195.2 1195.2
BEA (year 1) 16 13 21 12 27 13 18 17
BEA (year 2 onwards) 13 10 16 10 21 10 14 15
EMs: medication adherence electronic monitoring
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One of the objectives of this reform is to strengthen in the
pre-graduated cycle the clinical skills of pharmacists to
deliver advanced patient-oriented services in the
pre-graduated cycle. The curricula content influences the
dissemination of professional pharmacy services and must
accompany the evolution of the profession, according to
national needs. Moreover, the specific education required
to deliver the program can generate indirect revenues in
other fields of business, allowing the pharmacist to invest
time and skills in communicating with patients at risk for
nonadherence.
Variable costs were primarily driven by workforce time
(68%). We assume that this time will decrease and stabil-
ise in the medium term with routine program delivery
[32], providing a better profitability. Space cost was not
very high. However, this valuation considers the oppor-
tunity cost associated with the use of a private area for
the delivery of the program. Assuming that this area
already existed, the growing number of patients followed
could disrupt its previous use. Business diversification,
including new professional services, affects the spatial
organisation at the community pharmacy, notably asso-
ciated with the offer of activities with and without
appointments.
With our assumptions and the current national reim-
bursement system model, a minimum of 16 patients
must be follow up with to ensure a profit for the phar-
macy, with a range from 10 to 27 according to scenarios
assessed in sensitivity analyses. In real life, some patients
may stop the follow-up before one year, and the fre-
quency of interviews will depend on the patient’s needs.
Is this number realistic in terms of inclusion and
follow-up rates? The patient inclusion process into the
medication adherence program depends on several fac-
tors, which are specifically linked to the setting: the
needs of the targeted population of patients, the state of
the interprofessional collaboration, and the pharmacists’
ability to include patients. First, about 50% of chronic
patients do not take their medications as prescribed
[40]. Each professional has a role to play to support such
patients in the management of their medications, not-
ably the community pharmacist, as the first port of call
in primary health care and the specialist of medicines.
Due to the endemic nature of medication nonadherence,
a large proportion of chronic patients could reasonably
benefit from this service in a pharmacy. Second, the ex-
istence of local interprofessional networks has been
identified as one of the major factors for successfully
implementing a medication adherence program in com-
munity pharmacies [41, 42]. We observed at the PMU
that the inclusion in the program by the physician plays
a key factor. In fact, it is determinant that this program
is part of the medical care plan, as many patients rely on
this traditional way of therapeutic decision-making
process. The other barriers that may affect program suc-
cess are poor patient-pharmacist communication (result-
ing in an insufficient promotion of the program),
difficulty in integrating the program into the pharmacy
organisation, and insufficient pharmacist motivation
[42].
In our model, only one full-time equivalent (FTE)
pharmacist and one FTE technician followed up with
the entire cohort of patients. However, the management
of 16 patients only represents a 7% FTE for pharmacists
and a 4% FTE for technicians (9 and 5% respectively for
27 patients). In the context of a pharmacy, this implies a
solid management and planning of staff resources for
each basic and advanced activity. Strategically, we rec-
ommend training at least two pharmacists and techni-
cians to ensure a turnover in case of absence. Assuming
an amortisation over 5 years, the doubling of trained
professionals had a minimal impact on the break-even
point (see Table 2).
Regarding the generalisability of this cost analysis to
other contexts, the BEA depends on the national reim-
bursement system model. In our context, the “price” of
the service corresponds to a fee-for-service plus the sale
of pill boxes. The Swiss pharmacist can charge them
only if the patient is simultaneously prescribed at least
three chronic medications (resulting in three EMs). With
a fourth chronic medication or more, the pharmacist
can charge an additional polymedication check fee
(48.60 CHF every 6 months). Although the number of
tablets can affect adherence [40], these restrictions are
debatable as chronic patients with only one drug (e.g.,
HIV, multiple sclerosis or cancer patients) also need the
program. According to the PMU data, patients had an
average of 2 EMs over their entire follow-up period
[IQR: 1–3] [12]. Moreover, it is impossible to estimate
the potential hidden incomes generated by the delivery
of the program from the building of patient loyalty or
the increasing of the medication adherence, both of
which could add to the revenue.
The estimates or our analysis is not generalizable per
se as it is context-dependent. However, the BEA equa-
tion (see Fig. 2) can be applied to other healthcare con-
texts to either calculate the price of the service or the
number of patients to include in order to reach the local
break-even point. For instance, Noain et al. 2017 esti-
mated a potential medication review with follow-up
service price ranged from €237 to €628 per patient a
year in Spain, according to different scenarios including
professional level of the service provider (pharmacist in
charge/pharmacy owner), potential number of patients
receiving the service (60/120/180) and mark-up applied
(10/20/30/40%) [39].
Some methodological considerations should be noted
when interpreting these findings. BEA is a simplistic
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representation of reality. Although the estimated param-
eters are based on the experience of the PMU and expert
opinions, BEA assumed a similar variable cost for all pa-
tients. However, the pharmacy faces a variety of patients,
leading to a range of variable costs in the type and ex-
tent of nonadherence issues, frequency of visits, number
of EMs, duration of interview and duration of follow-up.
For instance, at the PMU, patient retention in the pro-
gram is longer in patients with more serious nonadher-
ence issues than in patients with less serious issues. This
repartition is nevertheless unknown in the community
and different in each pharmacy setting. Prospective stud-
ies should assess this variability in real life. The major
unpredicted event that occurs in the IMAP program is
when patients do not show up and the visit is resched-
uled. We have not taken this uncertainty into account in
our model as extra-cost because the pharmacist is di-
rected to another clinical activity when this situation
happens.
Conclusions
This pragmatic analysis can be used as a template to esti-
mate the implementation costs and assess the economic
feasibility and viability of a professional pharmacy service
from the provider’s perspective. In a Swiss context, the im-
plementation in community pharmacies of the described
interprofessional medication adherence program for
chronic patients treated with at least three medications
seems to be profitable; the current medication adherence
support fee-for-service system allows pharmacists to reach
a break-even point with at least 13 patients. These findings
are important to community pharmacists in deciding
whether to implement the service and can guide their
business plans and implementation strategies. The replica-
tion of similar analyses in other settings and countries is
paramount for a better understanding of the feasibility
and implementation costs of medication adherence pro-
grams, as well as other advanced services, in routine phar-
macy care. Implementation research can also aims to
optimize the service design and process to reduce its cost.
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